NCT04838782

Brief Summary

Patients with recurrent Glioblastoma (GBM) are commonly presented to surgeons, along with the question of whether or not to re-resect the recurrence. There is no Level 1 evidence to support a role for repeat surgery in this context, but a multitude of observational research suggests that repeat surgery may improve quality survival. Unfortunately, these studies all suffer from selection bias. The goal of this study is to provide a care trial context to help neurosurgeons manage patients presenting with recurrent GBM, with no additional risks, tests, or interventions than what they would normally encounter in routine care. Secondary goals include a test of the hypothesis that repeat resection can improve median overall survival, and that it can increase the number of days of survival outside of a hospital/nursing/palliative care facility.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 4, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 9, 2021

Completed
5 months until next milestone

Study Start

First participant enrolled

August 26, 2021

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 24, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 24, 2025

Completed
Last Updated

July 8, 2025

Status Verified

July 1, 2025

Enrollment Period

3.6 years

First QC Date

April 4, 2021

Last Update Submit

July 2, 2025

Conditions

Keywords

rGBM, repeat GBM, recurrent high grade astrocytoma

Outcome Measures

Primary Outcomes (1)

  • Length of Overall Survival

    The primary outcome is time to death from any cause, starting from the time of inclusion.

    Follow-up for 5 Years or until death

Secondary Outcomes (5)

  • Total length of hospitalization / palliative care / nursing home

    Follow-up for 5 Years or until death

  • Discharge to a location other than home

    Follow-up for 5 Years or until death

  • Total number of days spent outside a hospital or nursing care facility.

    Follow-up for 5 Years or until death

  • Incidence of peri-operative non-neurological complications (wound infection, CSF leaks)

    Follow-up for 5 Years or until death

  • Incidence of new significant neurological deficits after surgery (defined as new or substantially worsened aphasia, or new weakness (MRC power < 3 in one or more limbs).

    Follow-up for 5 Years or until death

Study Arms (2)

Repeat Surgical Resection

EXPERIMENTAL

Standard surgical operative management according to local practices.

Procedure: Repeat Surgical Management of Recurrent GBM

Management Without Re-operation

ACTIVE COMPARATOR

Non-surgical management with standard care according to local practices.

Procedure: Repeat Surgical Management of Recurrent GBM

Interventions

Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).

Management Without Re-operationRepeat Surgical Resection

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age ≥ 18
  • Previously histologically confirmed and surgically resected Glioblastoma
  • Previous craniotomy for open tumor resection (needle biopsies alone do not count as resection)
  • The attending surgeon considers re-operation may improve quality survival

You may not qualify if:

  • Informed consent not possible

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alberta Division of Neurosurgery

Edmonton, Alberta, T6G 2B7, Canada

Location

Related Publications (24)

  • Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100. doi: 10.1093/neuonc/noz150.

    PMID: 31675094BACKGROUND
  • Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96. doi: 10.1158/1055-9965.EPI-14-0275. Epub 2014 Jul 22.

    PMID: 25053711BACKGROUND
  • Yahia-Cherif, M., De Witte, O., Mélot, C., & Lefranc, F. (2019). P14.56 Recurrent Glioblastomas: Should we operate a second and even a third time. Neuro-Oncology, 21(Suppl 3), iii80.

    BACKGROUND
  • De Bonis P, Anile C, Pompucci A, Fiorentino A, Balducci M, Chiesa S, Lauriola L, Maira G, Mangiola A. The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg. 2013 Jan;115(1):37-43. doi: 10.1016/j.clineuro.2012.04.005. Epub 2012 Apr 24.

    PMID: 22537870BACKGROUND
  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. doi: 10.1056/NEJMoa043330.

    PMID: 15758009BACKGROUND
  • Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol. 2013 Jan;15(1):4-27. doi: 10.1093/neuonc/nos273. Epub 2012 Nov 7.

    PMID: 23136223BACKGROUND
  • Gempt J, Forschler A, Buchmann N, Pape H, Ryang YM, Krieg SM, Zimmer C, Meyer B, Ringel F. Postoperative ischemic changes following resection of newly diagnosed and recurrent gliomas and their clinical relevance. J Neurosurg. 2013 Apr;118(4):801-8. doi: 10.3171/2012.12.JNS12125. Epub 2013 Feb 1.

    PMID: 23373806BACKGROUND
  • Barbagallo GM, Jenkinson MD, Brodbelt AR. 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg. 2008 Jun;22(3):452-5. doi: 10.1080/02688690802182256.

    PMID: 18568742BACKGROUND
  • Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008 May;69(5):506-9; discussion 509. doi: 10.1016/j.surneu.2007.03.043. Epub 2008 Feb 8.

    PMID: 18262245BACKGROUND
  • Chen MW, Morsy AA, Liang S, Ng WH. Re-do Craniotomy for Recurrent Grade IV Glioblastomas: Impact and Outcomes from the National Neuroscience Institute Singapore. World Neurosurg. 2016 Mar;87:439-45. doi: 10.1016/j.wneu.2015.10.051. Epub 2015 Nov 14.

    PMID: 26585720BACKGROUND
  • Hervey-Jumper SL, Berger MS. Reoperation for recurrent high-grade glioma: a current perspective of the literature. Neurosurgery. 2014 Nov;75(5):491-9; discussion 498-9. doi: 10.1227/NEU.0000000000000486.

    PMID: 24991712BACKGROUND
  • Franceschi E, Omuro AM, Lassman AB, Demopoulos A, Nolan C, Abrey LE. Salvage temozolomide for prior temozolomide responders. Cancer. 2005 Dec 1;104(11):2473-6. doi: 10.1002/cncr.21564.

    PMID: 16270316BACKGROUND
  • Goldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS. The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg. 2018 Nov 1;129(5):1231-1239. doi: 10.3171/2017.6.JNS17393. Epub 2018 Jan 5.

    PMID: 29303449BACKGROUND
  • Lu VM, Jue TR, McDonald KL, Rovin RA. The Survival Effect of Repeat Surgery at Glioblastoma Recurrence and its Trend: A Systematic Review and Meta-Analysis. World Neurosurg. 2018 Jul;115:453-459.e3. doi: 10.1016/j.wneu.2018.04.016. Epub 2018 Apr 11.

    PMID: 29654958BACKGROUND
  • Zhao YH, Wang ZF, Pan ZY, Peus D, Delgado-Fernandez J, Pallud J, Li ZQ. A Meta-Analysis of Survival Outcomes Following Reoperation in Recurrent Glioblastoma: Time to Consider the Timing of Reoperation. Front Neurol. 2019 Mar 26;10:286. doi: 10.3389/fneur.2019.00286. eCollection 2019.

    PMID: 30984099BACKGROUND
  • Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Ronning P, Scheie D, Vik A, Meling TR. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand. 2010 Sep;122(3):159-67. doi: 10.1111/j.1600-0404.2010.01350.x. Epub 2010 Mar 18.

    PMID: 20298491BACKGROUND
  • Raymond J, Darsaut TE, Altman DG. Pragmatic trials can be designed as optimal medical care: principles and methods of care trials. J Clin Epidemiol. 2014 Oct;67(10):1150-6. doi: 10.1016/j.jclinepi.2014.04.010. Epub 2014 Jul 16.

    PMID: 25042688BACKGROUND
  • Patel M, Au K, Davis FG, Easaw JC, Mehta V, Broad R, Chow MMC, Hockley A, Kaderali Z, Magro E, Nataraj A, Scholtes F, Chagnon M, Gevry G, Raymond J, Darsaut TE. Clinical Uncertainty and Equipoise in the Management of Recurrent Glioblastoma. Am J Clin Oncol. 2021 Jun 1;44(6):258-263. doi: 10.1097/COC.0000000000000812.

    PMID: 33782334BACKGROUND
  • Schucht P. RESURGE: Surgery for recurrent Glioblastoma., https://clinicaltrials.gov/ct2/show/NCT02394626 (2020).

    BACKGROUND
  • Schwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis. 1967 Aug;20(8):637-48. doi: 10.1016/0021-9681(67)90041-0. No abstract available.

    PMID: 4860352BACKGROUND
  • Raymond J, Darsaut TE, Roy DJ. Recruitment in Clinical Trials: The Use of Zelen's Prerandomization in Recent Neurovascular Studies. World Neurosurg. 2017 Feb;98:403-410. doi: 10.1016/j.wneu.2016.11.052. Epub 2016 Nov 19.

    PMID: 27876665BACKGROUND
  • Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J, Lim M, Brem H, Quinones-Hinojosa A. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg. 2013 Apr;118(4):812-20. doi: 10.3171/2012.9.JNS1277. Epub 2012 Oct 19.

    PMID: 23082884BACKGROUND
  • Hoover JM, Nwojo M, Puffer R, Mandrekar J, Meyer FB, Parney IF. Surgical outcomes in recurrent glioma: clinical article. J Neurosurg. 2013 Jun;118(6):1224-31. doi: 10.3171/2013.2.JNS121731. Epub 2013 Mar 15.

    PMID: 23495879BACKGROUND
  • Patel M, Au K, Easaw JC, Davis FG, Young K, Mehta V, Bowden GN, Keough MB, Sankar T, Scholtes F, Chagnon M, L'Esperance G, Yuan Y, Gevry G, Raymond J, Darsaut TE. Repeat resection in recurrent glioblastoma (3rGBM) Trial: A randomized care trial. Neurochirurgie. 2022 Apr;68(3):262-266. doi: 10.1016/j.neuchi.2021.09.001. Epub 2021 Sep 14.

MeSH Terms

Conditions

GlioblastomaAstrocytoma

Condition Hierarchy (Ancestors)

GliomaNeoplasms, NeuroepithelialNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Glandular and EpithelialNeoplasms, Nerve Tissue
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 4, 2021

First Posted

April 9, 2021

Study Start

August 26, 2021

Primary Completion

March 24, 2025

Study Completion

March 24, 2025

Last Updated

July 8, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will share

Data will be made available upon reasonable request.

Shared Documents
STUDY PROTOCOL, ICF
Time Frame
Indefinitely

Locations